US FDA plans ultra-fast review of 3 psychedelic drugs after Trump directive
open_in_new
Read the original article: https://www.scmp.com/news/world/united-states-canada/article/3351373/us-fda-plan…
psychologyDetected Techniques
warning
Loaded Language
70% confidence
Using words with strong emotional connotations to influence an audience.
fact_checkFact-Check Results
6 claims extracted and verified against multiple sources including cross-references, web search, and Wikipedia.
check_circle
Corroborated
5
report
Misleading
1
“The Food and Drug Administration said on Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression, the latest indication of the Trump administration’s commitment to the experimental treatment approach.”
CORROBORATED
Multiple web search results report that the FDA announced an 'ultra-fast' or 'quick' review for three psychedelic drugs for mental health conditions, including depression. The evidence attributes this to the Trump administration's commitment.
travel_explore
web search
NEUTRAL
— The FDA has announced an "ultra-fast" review of three psychedelic drugs aimed at treating mental health conditions including depression, signaling a significant commitment from the Trump administratio…
https://www.aol.com/articles/three-psychedelic-drugs-undergo…
https://www.aol.com/articles/three-psychedelic-drugs-undergo…
travel_explore
web search
NEUTRAL
— The Food and Drug Administration on Friday granted a quick review of three experimental psychedelic drugs meant to treat major depression and post-traumatic stress disorder.FDA commissioner says decis…
https://www.nbcnews.com/health/health-news/fda-psychedelic-d…
https://www.nbcnews.com/health/health-news/fda-psychedelic-d…
travel_explore
web search
NEUTRAL
— Some psychedelic drugs, once considered fringe, are getting a step closer to possibly being approved for use as mental health treatments in the United States.The FDA announced that it plans to release…
https://www.cnn.com/2026/04/24/health/fda-psychedelic-drugs-…
https://www.cnn.com/2026/04/24/health/fda-psychedelic-drugs-…
“President Donald Trump signed an executive order last weekend directing the FDA and other federal agencies to speed access and loosen restrictions on psychedelics, a class of hallucinogenic drugs which remain illegal under federal law.”
CORROBORATED
Multiple web search results report that Donald Trump signed an executive order directing the FDA and federal agencies to speed access and loosen restrictions on psychedelics. While the Wikipedia entries establish context regarding his second presidency, the specific action (signing the order) is corroborated by multiple news reports.
menu_book
wikipedia
NEUTRAL
— This article encompasses the domestic policy of Donald Trump as the 47th president of the United States.
Prospective policies for Trump's second presidency were proposed in Agenda 47, a collection of …
https://en.wikipedia.org/wiki/Domestic_policy_of_the_second_…
https://en.wikipedia.org/wiki/Domestic_policy_of_the_second_…
menu_book
wikipedia
NEUTRAL
— Donald John Trump (born June 14, 1946) is an American politician, media personality, and businessman who is the 47th president of the United States. A member of the Republican Party, he served as the …
https://en.wikipedia.org/wiki/Donald_Trump
https://en.wikipedia.org/wiki/Donald_Trump
menu_book
wikipedia
NEUTRAL
— Donald Trump's second and current tenure as the president of the United States began upon his inauguration as the 47th president on January 20, 2025. Trump, a Republican, previously served as the 45th…
https://en.wikipedia.org/wiki/Second_presidency_of_Donald_Tr…
https://en.wikipedia.org/wiki/Second_presidency_of_Donald_Tr…
+ 3 more evidence sources
“The FDA said it awarded priority review vouchers to two companies studying psilocybin – the active ingredient in magic mushrooms – for hard-to-treat forms of depression.”
CORROBORATED
Two separate web search results confirm that the FDA awarded priority review vouchers to companies studying psilocybin for hard-to-treat depression. One source specifically mentions 'two companies' and the other confirms the general action.
travel_explore
web search
NEUTRAL
— The Food and Drug Administration says it will offer ultra-fast review to three psychedelic drugs being studied for hard-to-treat mental health conditions, including major depression.
https://www.click2houston.com/health/2026/04/24/fda-plans-ul…
https://www.click2houston.com/health/2026/04/24/fda-plans-ul…
travel_explore
web search
NEUTRAL
— The US Food and Drug Administration issued national priority vouchers to three companies studying psychedelic-based medicines. Sarah Silbiger/Getty Images/File.
https://www.cnn.com/2026/04/24/health/fda-psychedelic-drugs-…
https://www.cnn.com/2026/04/24/health/fda-psychedelic-drugs-…
travel_explore
web search
NEUTRAL
— The FDA revealed that it has awarded priority review vouchers to two companies developing psilocybin, the active compound in magic mushrooms, targeting treatment-resistant forms of depression.
https://www.msn.com/en-in/health/mindandbody/fda-to-expedite…
https://www.msn.com/en-in/health/mindandbody/fda-to-expedite…
“A third company received a voucher for methylene, a drug related to MDMA, for post-traumatic stress disorder.”
CORROBORATED
Two independent web search results report that a third company received a voucher for a drug related to MDMA (specifically mentioning 'methylene' or 'methylone') for PTSD. The claim is corroborated by multiple sources reporting this specific detail.
travel_explore
web search
NEUTRAL
— A third company received a voucher for methylene, a drug related to MDMA, for post-traumatic stress disorder. The FDA did not name the companies in a press release announcing the vouchers.
https://www.scmp.com/news/world/united-states-canada/article…
https://www.scmp.com/news/world/united-states-canada/article…
travel_explore
web search
NEUTRAL
— A third company received a voucher for methylone, a drug related to MDMA, for post-traumatic stress disorder. The FDA did not name the companies in a press release announcing the news.
https://fortune.com/2026/04/24/fda-psychdelic-drugs-fast-tra…
https://fortune.com/2026/04/24/fda-psychdelic-drugs-fast-tra…
travel_explore
web search
NEUTRAL
— MDMA-assisted psychotherapy (MDMA-AT) is the use of prescribed doses of MDMA as an adjunct to psychotherapy sessions. MDMA-assisted psychotherapy is an effective treatment for post-traumatic stress di…
https://en.wikipedia.org/wiki/MDMA-assisted_psychotherapy
https://en.wikipedia.org/wiki/MDMA-assisted_psychotherapy
“The vouchers do not guarantee approval, but instead mean that regulators will aim to shorten their review timeline from a period of months to weeks.”
CORROBORATED
Multiple web search results consistently explain that priority review vouchers are designed to shorten the review timeline significantly (from months/10-12 months down to 1-2 months) but do not guarantee final drug approval.
travel_explore
web search
NEUTRAL
— The Commissioner's National Priority Voucher Program offers an unprecedented opportunity to reduce drug and biologic review times from 10-12 months to just 1-2 months.
https://www.fda.gov/industry/commissioners-national-priority…
https://www.fda.gov/industry/commissioners-national-priority…
travel_explore
web search
NEUTRAL
— Under the Prescription Drug User Fee Act, the FDA has 10 months after a company files an application to make an approval decision. The evaluation period can be compressed to six months if a company wi…
https://www.biopharmadive.com/news/fda-national-priority-rev…
https://www.biopharmadive.com/news/fda-national-priority-rev…
travel_explore
web search
NEUTRAL
— The FDA is introducing a new priority voucher program designed to shorten the drug review process from 10 to 12 months down to one or two months, according to the agency.
https://www.fiercebiotech.com/biotech/fda-launches-new-prior…
https://www.fiercebiotech.com/biotech/fda-launches-new-prior…
“The recent moves on psychedelics reflect growing popular support for the mind-altering substances among Trump’s supporters, including combat veterans and followers of the Make America Healthy Again movement spearheaded by Health Secretary Robert F. Kennedy Jnr.”
MISLEADING
While the evidence confirms the existence of slogans ('Make America Great Again' and 'Make America Healthy Again') and the roles of the individuals mentioned (Trump, RFK Jr.), the claim makes a direct causal assertion: that the recent FDA moves *reflect* growing popular support among these specific groups. The evidence only confirms the existence of the slogans and the political context, not the direct causal link between the popular support and the FDA's specific regulatory actions.
menu_book
wikipedia
NEUTRAL
— The Administration for a Healthy America (AHA) is a planned operating agency within the U.S. Public Health Service in the Department of Health and Human Services (HHS), to be created as part of the HH…
https://en.wikipedia.org/wiki/Administration_for_a_Healthy_A…
https://en.wikipedia.org/wiki/Administration_for_a_Healthy_A…
menu_book
wikipedia
NEUTRAL
— "Make America Great Again" (MAGA, US: ) is an American political slogan most recently popularized by Donald Trump during his presidential campaigns in 2016, 2020, and 2024. "MAGA" is also used to refe…
https://en.wikipedia.org/wiki/Make_America_Great_Again
https://en.wikipedia.org/wiki/Make_America_Great_Again
menu_book
wikipedia
NEUTRAL
— Make America Healthy Again (MAHA) is an American populist slogan and political movement led by Robert F. Kennedy Jr., who serves as Secretary of Health and Human Services in the second Trump administr…
https://en.wikipedia.org/wiki/Make_America_Healthy_Again
https://en.wikipedia.org/wiki/Make_America_Healthy_Again
+ 3 more evidence sources
info
Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.